BioFinlandin jäsen

Finnadvance is developing radically innovative microfluidic chips and organ-on-chip platforms for safe, reliable and cost effect drug testing for pharma industry and academic and clinical research. Our platforms are especially valuable for developing therapies for rare diseases and to develop personalized medicine.

The main target customer group is pharmaceutical industry. Conventional drug discovery uses methods like animal testing which is inhuman, expensive, time consuming and unreliable. Drug candidates which pass animal tests usually fail in clinical phase. Our organ-on-chip and disease-on-chip cell culture platforms are designed to mimic conditions and functions in human organs to result in better and safer drugs for humans.

In addition, we are manufacturing electrical devices and sofware supporting the use of our chips. All products are sold under our AKITA brand. Finnadvances production facilties are in Oulu, our sales office is in Helsinki.